The function of oxytocin: A potential biomarker for prostate cancer diagnosis and promoter of prostate cancer

Oncotarget

Volumn 8, Issue 19, 2017, Pages 31215-31226

  Xu, Huan ^a   Fu, Shi ^a   Chen, Qi ^a   Gu, Meng ^a   Zhou, Juan ^a   Liu, Chong ^a   Chen, Yanbo ^a   Wang, Zhong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

APPL1; Metabolism; Oxytocin; Proliferation; Prostate cancer

Indexed keywords

BINDING PROTEIN; CASPASE 3; CYCLINE; OXYTOCIN; OXYTOCIN RECEPTOR; PROTEIN APPL1; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER TISSUE; CELL CYCLE; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OXYTOCIN BLOOD LEVEL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; WESTERN BLOTTING; BLOOD; CANCER STAGING; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; ODDS RATIO; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; TUMOR CELL LINE;

AGED; APOPTOSIS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; OXYTOCIN; PROSTATIC NEOPLASMS; RECEPTORS, OXYTOCIN; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 85019147179     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16107     Document Type: Article

References (43)

1. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer. 2005; 41:834-45. doi: 10.1016/j.ejca.2004.12.033
2. Fleshner N, Al Azab R. Prostate cancer: chemoprevention update 2005. Can J Urol. 2005; 12:2-4
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 CA Cancer J Clin. 2012; 62:10-29. doi: 10.3322/caac.20138
4. Hussain A, Dawson N. Management of advanced/metastatic prostate cancer: 2000 update. Oncology (Williston Park). 2000; 14:1677-88; discussion 88, 91-4
5. Moses KA, Utuama OA, Goodman M, Issa MM. The association of diabetes and positive prostate biopsy in a US veteran population. Prostate Cancer Prostatic Dis. 2012; 15:70-4. doi: 10.1038/pcan.2011.40
6. Lima GA, Corrêa LL, Gabrich R, Miranda LC, Gadelha MR. IGF-I, insulin and prostate cancer. Arquivos Brasileiros De Endocrinologia E Metabologia. 2009; 53:969-75
7. Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate. 2008; 68:1592-8
8. Chang S, Hursting S, Contois J, Strom S, Yamamura Y, Babaian R, Troncoso P, Scardino P, Wheeler T, Amos C. Leptin and prostate cancer. Prostate. 2001; 46:62-7
9. Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, Tsutsumi Y, Nagaishi R, Tanabe M, Morinaga H. Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth. Diabetes. 2014; 63:3891-905
10. Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A, Register T, Cline JM, D'Agostino R, Danial N. Behavioral stress accelerates prostate cancer development in mice. Journal of Clinical Investigation. 2013; 123:874-86
11. Kluth LA, Shariat SF, Kratzik C, Tagawa S, Sonpavde G, Rieken M, Scherr DS, Pummer K. The hypothalamicpituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World Journal of Urology. 2014; 32:669-76
12. Whittington K, Assinder S, Gould M, Nicholson H. Oxytocin, oxytocin-associated neurophysin and the oxytocin receptor in the human prostate. Cell Tissue Res. 2004; 318:375-82. doi: 10.1007/s00441-004-0968-5
13. Nicholson HD. Oxytocin: a paracrine regulator of prostatic function. Rev Reprod. 1996; 1:69-72
14. Whittington K, Connors B, King K, Assinder S, Hogarth K, Nicholson H. The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate. Prostate. 2007; 67:1132-42. doi: 10.1002/pros.20612
15. Xu H, Fu S, Chen Y, Chen Q, Gu M, Liu C, Qiao Z, Zhou J, Wang Z. Oxytocin: its role in the benign prostatic hyperplasia (BPH) via the ERK pathway. Clin Sci (Lond). 2017 doi: 10.1042/CS20170030
16. Zhong M, Boseman ML, Millena AC, Khan SA. Oxytocin induces the migration of prostate cancer cells: involvement of the Gi-coupled signaling pathway. Mol Cancer Res. 2010; 8:1164-72. doi: 10.1158/1541-7786.MCR-09-0329
17. Assinder SJ, Davies K, Surija J, Liu-Fu F. Oxytocin differentially effects 3β-hydroxysteroid dehydrogenase and 5a-reductase activities in prostate cancer cell lines. Peptides. 2015; 71:149-55
18. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, Fang Q, Christroberts CY, Hong JY, Kim RY. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nature Cell Biology. 2006; 8:516-23
19. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. American Journal of Physiology Endocrinology & Metabolism. 2009; 296:E22-E36
20. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994; 54:5474-8
21. Thackare H, Nicholson HD, Whittington K. Oxytocin-its role in male reproduction and new potential therapeutic uses. Hum Reprod Update. 2006; 12:437-48. doi: 10.1093/humupd/dmk002
22. Nicholson HD, Jenkin L. Oxytocin and prostatic function. Adv Exp Med Biol. 1995; 395:529-38
23. Bodanszky M, Sharaf H, Roy JB, Said SI. Contractile activity of vasotocin, oxytocin, and vasopressin on mammalian prostate. Eur J Pharmacol. 1992; 216:311-3
24. Frayne J, Townsend D, Nicholson HD. Effects of oxytocin on sperm transport in the pubertal rat. J Reprod Fertil. 1996; 107:299-306
25. Assinder SJ, Johnson C, King K, Nicholson HD. Regulation of 5alpha-reductase isoforms by oxytocin in the rat ventral prostate. Endocrinology. 2004; 145:5767-73. doi: 10.1210/en.2004-0711
26. Assinder SJ, Davies K, Surija J, Liu-Fu F. Oxytocin differentially effects 3beta-hydroxysteroid dehydrogenase and 5alpha-reductase activities in prostate cancer cell lines. Peptides. 2015; 71:149-55. doi: 10.1016/j. peptides.2015.07.015
27. Altirriba J, Poher AL, Caillon A, Arsenijevic D, Veyrat-Durebex C, Lyautey J, Dulloo A, Rohner-Jeanrenaud F. Divergent Effects of Oxytocin Treatment of Obese Diabetic Mice on Adiposity and Diabetes. Endocrinology. 2014: en20141466. doi: 10.1210/en.2014-1466
28. Arletti R, Benelli A, Bertolini A. Oxytocin inhibits food and fluid intake in rats. Physiol Behav. 1990; 48:825-30
29. Xu H, Jiang HW, Ding GX, Zhang H, Zhang LM, Mao SH, Ding Q. Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and metaanalysis. Diabetes Res Clin Pract. 2013; 99:241-9. doi: 10.1016/j.diabres.2012.12.003
30. Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG. Oxytocin-and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004; 11:871-85. doi: 10.1677/erc.1.00803
31. Sapino A, Cassoni P, Stella A, Bussolati G. Oxytocin receptor within the breast: biological function and distribution. Anticancer Res. 1998; 18:2181-6
32. Cassoni P, Sapino A, Deaglio S, Bussolati B, Volante M, Munaron L, Albini A, Torrisi A, Bussolati G. Oxytocin is a growth factor for Kaposi's sarcoma cells: evidence of endocrineimmunological cross-talk. Cancer Res. 2002; 62:2406-13
33. Cassoni P, Marrocco T, Bussolati B, Allia E, Munaron L, Sapino A, Bussolati G. Oxytocin induces proliferation and migration in immortalized human dermal microvascular endothelial cells and human breast tumor-derived endothelial cells. Mol Cancer Res. 2006; 4:351-9. doi: 10.1158/1541-7786.MCR-06-0024
34. Imanieh MH, Bagheri F, Alizadeh AM, Ashkani-Esfahani S. Oxytocin has therapeutic effects on cancer, a hypothesis. Eur J Pharmacol. 2014; 741:112-23. doi: 10.1016/j. ejphar.2014.07.053
35. Vlahakis SR, Villasis-Keever A, Gomez T, Vanegas M, Vlahakis N, Paya CV. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J Immunol. 2002; 169:5546-54
36. Zhong M, Clarke S, Vo BT, Khan SA. The essential role of Gialpha2 in prostate cancer cell migration. Mol Cancer Res. 2012; 10:1380-8. doi: 10.1158/1541-7786.MCR-12-0219
37. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, Fang Q, Christ-Roberts CY, Hong JY, Kim RY, Liu F, Dong LQ. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol. 2006; 8:516-23. doi: 10.1038/ncb1404
38. Zhai J, Song J, Zhu C, Wu K, Yao Y, Li N. Expression of APPL1 is correlated with clinicopathologic characteristics and poor prognosis in patients with gastric cancer. Current Oncology. 2016; 23:e95
39. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab. 2009; 296:E22-36. doi: 10.1152/ajpendo.90731.2008
40. Johnson IR, Parkinson-Lawrence EJ, Shandala T, Weigert R, Butler LM, Brooks DA. Altered endosome biogenesis in prostate cancer has biomarker potential. Mol Cancer Res. 2014; 12:1851-62. doi: 10.1158/1541-7786.MCR-14-0074
41. Rhee H, Vela I, Chung E. Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer. Horm Cancer. 2016; 7:75-83. doi: 10.1007/s12672-015-0238-x
42. Porcaro AB, Petrozziello A, Ghimenton C, Migliorini F, Sava T, Caruso B, Cocco C, Romano M, Artibani W. Along the pituitary-testis-prostate axis, serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups. Anticancer Res. 2012; 32:5015-22
43. Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A, Register T, Cline JM, D'Agostino R Jr, Danial N, Datta SR, Kulik G. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest. 2013; 123:874-86. doi: 10.1172/JCI63324